HAART in HIV/AIDS Treatments: Future Trends

Title:HAART in HIV/AIDS Treatments: Future Trends

Volume: 18 Issue: 1

Author(s): Da-Yong Lu*, Hong-Ying Wu, Nagendra Sastry Yarla, Bin Xu, Jian Ding and Ting-Ren Lu

Affiliation:

• School of Life Sciences, Shanghai University, Shanghai 200444,China

Keywords: HAART, antiviral therapy, HIV cure, drug delivery system, medicinal chemistry, HIV latency, HIV reservoirs, integrase inhibitors, pharmacogenomics, biotherapy.

Abstract: AIDS (acquired immune deficient syndrome) is a deadly human viral infectious disease caused by HIV (human immune-deficient virus) infection. Almost every AIDS patient losses his/her life before mid 1990s. AIDS was once the 1st disease killer in US (1993). After one decade hard work, antiviral drug cocktails-high active anti-retroviral therapy (HAART) have been invented for almost all HIV infection treatments. Due to the invention of HAART, 80-90% HIV/AIDS patients still effectively response to HAART for deadly AIDS episode controls and life saving. Yet, this type of HIV therapeutics is incurable. HIV/AIDS patients need to take HAART medications regularly and even life-long. To counteract this therapeutic drawback, more revolutionary efforts (different angles of therapeutic modes/attempts) are urgently needed. In this article, the major progresses and drawbacks of HIV/AIDS chemotherapy (HAART) to HIV/AIDS patients have been discussed. Future trends (updating pathogenesis study, next generations of drug developments, new drug target discovery, different scientific disciplinary and so on) are highlighted.

Cite this article as:

Lu Da-Yong*, Wu Hong-Ying, Yarla Sastry Nagendra , Xu Bin, Ding Jian and Lu Ting-Ren , HAART in HIV/AIDS Treatments: Future Trends, Infectious Disorders - Drug Targets 2018; 18 (1) . https://dx.doi.org/10.2174/1871526517666170505122800